** Shares of Cidara Therapeutics CDTX.O edge lower after hours as co looks to capitalize on big pop in its stock to raise equity
** CDTX shares soared ~114% to close at $44.95, nearly 4-yr high, after co early Mon announced positive topline results from Phase II trial for CD388, a non-vaccine preventative of seasonal influenza
** Co said study met primary and secondary efficacy endpoints for all dose groups
** After the bell, San Diego-based firm commenced $250 mln stock offering
** JP Morgan, Morgan Stanley, Guggenheim and Cantor are jt bookrunners
** Cidara has ~13 mln shares outstanding for current market cap of roughly $580 mln, per recent 10-Q filing
** Through Fri close, CDTX shares had lost ~22% in 2025
** All 7 analysts are bullish on CDTX with median PT of $56.50, up from $40 a month ago, latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.